Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004Rritual Superfoods Ready to Launch Amazon Store in USAAtai Life Sciences Is Setting The Stage For The Largest IPO The Psychedelics Sector Has Seen To DateEntheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available fMajor U.S. States Are Taking A Serious Look At Decriminalizing Psychedelic Compounds For The Treatment Of Mental IllnessMAPS Canada Is Leading The Global Charge To Commercialize Psychedelic TherapiesBetterLife Pharma Appoints Henri Sant-Cassia of The Conscious Fund to its Board of DirectorsMindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic MedicineTryp Therapeutics Partners with Alcami for Proprietary FormulationsHAVN Life Secures Production & Supply Agreement to Expand Retail Product OfferingsCybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery MechanismsNuminus Wellness Is One Of The Shining Stars Of The Psychedelic SectorPsychedelic Stocks Are Starting To Get Some Serious Traction In The Mainstream MediaMAPS Canada Is Leading The Way For Psychedelic Use Cases In Modern MedicineRritual Superfoods Initiates Canadian Retail Growth Strategy Signing with Ultimate Sales CanadaNuminus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for SevTryp Therapeutics Partners with Clinlogix for Clinical Trial SupportTryp Therapeutics Partners with Fluence for Psychotherapy DesignTryp Therapeutics Announces Q2 2021 Financial ResultsRritual Announces CROSSMARK Partnership to Optimize Retail Growth

Technical420 Site Search

Returned 12 result(s).

Psychedelic Stocks Are Starting To Get Some Serious Traction In The Mainstream Media

2021 has been a banner year for the psychedelic therapy market and we believe the industry is in the early innings of a major growth cycle.  With interest growing for data from biotech and non-profit research firms that are conducting Food and Drug Administration (FDA) clinical trials on psychedelic therapies.…

3 Drug Development Companies Leveraging Psychedelic Compounds In Clinical Trials

Although 2020 was a banner year for the psychedelic therapy market, we expect 2021 to be an even better year for the sector as leading biotech firms are set to report Phase 3 Food and Drug Administration (FDA) clinical trial data. We have seen the psychedelic sector evolve over the…

5 Clinical Trials Leveraging Psychedelics That Investors Need To Be Watching

During the last year, we have seen a significant increase in the number of pre-clinical and clinical studies on psychedelic therapies and this is a trend that caught our attention. When most people think about the psychedelic industry, they tend to overlook the potential that is associated with the commercialization…

The Psychedelic Sector Is Getting A Major Momentum Boost Post U.S. Election

The US election proved to be a catalyst for the psychedelic therapy industry after two major ballot initiatives were passed in the District of Columbia and in Oregon. According to the Associated Press, D.C. voters passed legislation that would make the possession and use of certain psychedelic plants the lowest…

3 Psychedelic Stocks With The Highest Chance Of Successfully Bringing A Psychedelic Therapy To Market

One of the most exciting growth stories in the biotech sector relates to the studies on psychedelic substances. The companies that focus on this vertical are working to develop treatments for mental illness. We are bullish on this opportunity due to the size of the total addressable market (TAM). Although…

Compass Pathways and Cybin Corp Are Two Of The Most Compelling Enterprises We Have Seen In The Psychedelics Sector Thus Far

A few weeks ago, Compass Pathways (CMPS) completed an initial public offering (IPO) on the Nasdaq. By accomplishing this, Compass became the first psychedelic therapy company to list on a big-board U.S. exchange.   Compass’ IPO was nothing short of significant success, and the listing represented a significant milestone for…

Cybin Corp. Is A Best In Class Psychedelics Company When Compared To Industry Bellwether Compass Pathways

Last week, Compass Pathways (CMPS) commenced trading on the Nasdaq and became the first psychedelic drug company to go public on a major U.S. stock exchange. When Compass filed to go public, the deal generated substantially more interest from investors than expected. As a result, the psychedelic therapy company upsized…

Compass Pathways Is Set To Take Psychedelics Mainstream With An IPO On The Nasdaq

2020 has been a banner year for the psychedelic sector and we believe that the industry is in the early stages of a major growth cycle. Last week, Compass Pathways announced a major milestone and filed to go public on the Nasdaq Global Market under the symbol CMPS. The leading…

Is Psilocybin The Next Cannabis? These Two Bellwethers Make Us Think So

The psychedelic therapy market is an emerging industry that is not even in the first inning of a major growth cycle and there are several companies already working to bring breakthrough therapies for a range of mental health conditions to market. 2020 has been a banner year for the psychedelic…

7 Companies Focused On Psychedelic Therapies For Treating Mental Illness

2020 has been a challenging year for the global economy as the world tries to recover from the COVID-19 outbreak. Following the outbreak, we have noticed a bifurcation in the markets where some sectors would considerably outperform others. For example, companies like Clorox and Amazon have reported impressive growth during…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link